Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Monte Haber

Sports Medicine Wayne, NJ Medical Doctor

NPI 1669567202 CMS profile 347609

1680 Route 23, Suite 250, Wayne, NJ 07470

Open in the dashboard

General payments

$2,748

104 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Monte Haber of Wayne, NJ is reported in the CMS Open Payments database as having received $2,748 across 104 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $828 18
2024 General $259 13
2023 General $324 13
2022 General $484 14
2021 General $189 9
2020 General $211 10
2019 General $452 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Monte Haber
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Monte Haber were reported at $828. Among 250 Sports Medicine profiles paid that year, the median was $119 and the middle half received between $39 and $268.

Show as a table
Year Monte Haber Sports Medicine median Middle half National median
2019 $452 $125 $45–$345 $163
2020 $211 $96 $33–$311 $114
2021 $189 $113 $34–$344 $132
2022 $484 $100 $35–$293 $149
2023 $324 $100 $42–$324 $160
2024 $259 $139 $45–$319 $164
2025 $828 $119 $39–$268 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Curonix LLC $428 6 payments
  2. Stryker Corporation $375 6 payments
  3. SPR Therapeutics, Inc $313 6 payments
  4. Scilex Pharmaceuticals Inc. $235 17 payments
  5. Boston Scientific Corporation $214 11 payments
  6. Allergan Inc. $153 11 payments
  7. Djo, LLC $123 3 payments
  8. Relievant Medsystems, Inc. $122 1 payment
  9. BIOTRONIK NRO, Inc. $109 5 payments
  10. SI-BONE, Inc. $72 4 payments
  11. Other $604 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,221 100 payments
  2. Travel and Lodging $527 4 payments
Products named General payments · program years 2019–2025
  1. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $428 6 payments
  2. SPRINT PNS System $313 6 payments
  3. ORTHOMAP $209 3 payments
  4. BOTOX $153 11 payments
  5. Intracept Pain $122 1 payment
  6. Intracept Pain $122 1 payment
  7. ZTLido $111 8 payments
  8. Prospera $109 5 payments
  9. SPECTRA WAVEWRITER $74 4 payments
  10. ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH $70 5 payments
  11. Other $1,214 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

85

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$2,011

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

0%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lidocaine Generic 15 $1,233
Gabapentin Generic 53 $480
Pregabalin Generic 17 $299

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$59,839

Of which drugs: $2,142

Medicare patients

153

Average age 76

Services billed

1,182

98 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 36%
Diabetes 33%
Chronic kidney disease 23%
Osteoporosis 23%
Cancer 22%
Depression 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 18 26 $147

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record